The validation and bias-monitoring program designed to run alongside the first design-partner deployments. Each block is pilled to distinguish what's a finalized study design from what's gated on cohort availability.
PlannedValidation cohort target
~10k women across 3-5 design-partner provider organizations, stratified by menopause stage (peri / post), symptom-cluster severity, and care-access setting. Recruitment begins after the first design-partner BAA is in force.
DesignedPrimary endpoints
Care-Router pathway concordance vs. blinded clinician adjudication; symptom-burden trajectory (vasomotor / sleep / mood) at 30 / 90 days post-intake; time-to-MSCP-visit for high-burden cohorts.
DesignedReference standard
Two-clinician adjudication of pathway routing on a stratified random sample, blinded to model output. Disagreements resolved by a third senior reviewer.
PlannedStatistical plan
Pre-registered with the validation protocol; primary analysis is the pathway-concordance Cohen's kappa with 95% confidence intervals. Sensitivity analyses by age, ethnicity, and care-access setting.
DesignedBias monitoring
Subgroup pathway-distribution + concordance reported per cohort dimension (age, race / ethnicity, insurance status, geography) at the same cadence as the validation report. Designed; cadence depends on cohort enrollment rate.
PlannedIRB / ethics
Validation studies submitted to the design-partner organization's IRB. The platform's prototype use of synthetic personas is not human-subjects research.